Last updated: June 18, 2026
Veloxis Pharmaceuticals v. Alkem Laboratories (1:24-cv-00784): Litigation Summary, Patent Theories, and Generic Entry Risk
Veloxis Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., No. 1:24-cv-00784 (D. [district not provided]), is a 2024 Hatch-Waxman patent litigation matter brought by Veloxis against Alkem. The key business issue is whether Alkem’s proposed generic product infringes one or more Orange Book-listed patents for the Veloxis reference product and whether Veloxis can secure an injunction or delay FDA approval through a favorable infringement and validity record.
Actionable litigation posture in this record: No dispositive facts (asserted patent numbers, listed drug, Orange Book patents, Paragraph IV details, case outcome events, Markman rulings, Teva/Alkem settlement terms, or FDA status) are included in the prompt. Without those primary identifiers, a complete, accurate litigation summary and patent-by-patent analysis cannot be produced under a strict accuracy standard.
What patent claims are asserted in Veloxis v. Alkem 1:24-cv-00784?
Answer (from provided information): Not specified.
Which Orange Book patents are at issue?
Not specified.
What infringement theory is alleged (literal, doctrine of equivalents, induced/contributory)?
Not specified.
What validity challenges are pled (35 USC §§ 102, 103, 112, obviousness-type double patenting)?
Not specified.
When was the case filed and what are the key procedural milestones?
Answer (from provided information): The action is filed in 2024 and docketed as 1:24-cv-00784.
Service, initial pleadings, and responsive deadlines
Not specified.
Markman / claim construction schedule
Not specified.
Discovery phase status and expert disclosures
Not specified.
Summary judgment, trial date, or dispositive motion outcomes
Not specified.
What Paragraph IV certifications did Alkem file for its ANDA (or what waiver applies)?
Answer (from provided information): Not specified.
Which listed patents were challenged
Not specified.
Is the certification type: “IV,” “I,” “II,” or “III”?
Not specified.
Has FDA approval been stayed under 21 USC § 355(j)?
Not specified.
How strong is the Veloxis patent estate in this case?
Answer (from provided information): Not specified.
What is the patent cadence (drug substance, formulation, method-of-use, polymorph/crystal, manufacturing)?
Not specified.
Are there enforceable “secondary” patents at issue?
Not specified.
What defenses are typically raised by Alkem in Hatch-Waxman suits, and what is the likely posture here?
Answer (from provided information): The prompt does not provide the defense allegations or the claim chart record needed to tie defenses to specific asserted patents.
Non-infringement defenses
Not specified.
Invalidity defenses
Not specified.
Prosecution history estoppel or indefiniteness arguments
Not specified.
What is the litigation outcome in Veloxis v. Alkem 1:24-cv-00784?
Answer (from provided information): Not specified.
Were there settlements, consent judgments, or stipulated dismissals?
Not specified.
Did the court grant preliminary injunction or deny it?
Not specified.
Was there a final judgment on infringement and validity?
Not specified.
How does this case affect generic entry risk for Alkem?
Answer (from provided information): Not specified because the record needed to translate litigation status into FDA timing (including any settlement stay period, injunction scope, or “carve-out” product design changes) is not included.
Injunction scope and “design-around” risk
Not specified.
Regulatory timeline impact (180-day exclusivity, stays, final approval)
Not specified.
Commercial exposure if litigation stays are lifted
Not specified.
What is the Orange Book status of the asserted Veloxis patents, and when do they expire?
Answer (from provided information): Not specified.
Which patents expire first (submission order)
Not specified.
What is the exclusivity overlay (5-year NCE, 3-year new clinical investigations, 7-year orphan, BLA timing, etc.)
Not specified.
Any pediatric exclusivity or patent term adjustments
Not specified.
How does Alkem’s ANDA strategy compare with other challengers in the same IP portfolio?
Answer (from provided information): Not specified.
Other Paragraph IV filers in the same Orange Book family
Not specified.
Differences in claimed formulation, crystal form, or dosing strength
Not specified.
Key litigation timeline (docket-based)
Not computable from provided information.
Key Takeaways
- The prompt identifies the matter as Veloxis Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., No. 1:24-cv-00784, filed in 2024.
- No asserted patent numbers, Orange Book listing, Paragraph IV certifications, procedural milestones, or outcomes are included.
- Under an accuracy-first standard, a patent-by-patent infringement/validity analysis and a generic entry impact assessment cannot be completed from the supplied content.
FAQs
-
What is the case caption and docket number for Veloxis vs. Alkem?
Veloxis Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., No. 1:24-cv-00784.
-
Is Veloxis v. Alkem a Paragraph IV ANDA litigation?
The prompt does not state Paragraph IV details.
-
Does the case involve drug substance, formulation, or method-of-use patents?
The prompt does not list the patent types asserted.
-
Has Alkem launched “at risk” or received final FDA approval?
The prompt does not include FDA approval or launch status.
-
What court has jurisdiction over 1:24-cv-00784?
The prompt does not provide the district or judge.
References
- Veloxis Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., No. 1:24-cv-00784 (filed 2024).
